|to About the Eye
Facts About Diabetic Eye Disease
There are approximately 16 million Americans who have either Type I (juvenile onset) or Type II (adult onset)
diabetes. All are at risk of developing sight-threatening eye diseases that are common complications of diabetes.
Although early detection and timely treatment can substantially reduce the risk of severe visual loss or blindness
from diabetic eye disease, many people at risk are not having their eyes examined regularly to detect these
problems before they impair vision. Increased awareness of the sight-saving benefits of annual eye examinations
through dilated pupils is essential to reduce the significant social and personal costs of diabetic eye disease.
What is diabetic eye disease?
Diabetic eye disease refers to a group of sight-threatening eye problems that people with diabetes may develop
as a complication of the disease. They include:
What is the most common diabetic eye disease?
Diabetic retinopathy. The NEI estimates that of the approximately 10.5 million Americans who have diagnosed
diabetes, between 40-45 percent have some degree of diabetic retinopathy. Between 600,000-700,000
Americans have diabetic retinopathy severe enough to cause vision loss. As many as 24,000 people go blind
from this disorder annually, making it a leading cause of blindness among working-age Americans.
What is the cost of diabetic retinopathy?
It is estimated that a year of blindness costs the U.S. Government approximately $13,607 annually per person in
Social Security benefits, lost income tax revenue, and health care expenditures. If Americans at risk for
developing diabetic eye disease were regularly screened and treated to preserve their sight, the net annual
savings to the Government would be more than $100 million.
What causes it?
Diabetic retinopathy is a complex disease. Although scientists understand much about the disease's natural
history, they are still unclear about its specific pathological causes. There is, however, a consensus that diabetic
retinopathy probably does not stem from a single retinal change. Rather, the disease may be triggered by a
combination of biochemical, metabolic, and hematologic abnormalities.
In people with diabetes, three metabolic and hematologic changes are suspected of being involved in the early
stages of diabetic retinopathy:
These abnormalities may cause certain cells to die inside the retinal blood vessels. This leads to altered blood
flow, increased blood vessel permeability, and the growth of certain blood vessel components. As a result, tiny
outcroppings--called microaneurysms--may bulge from the weak blood vessel walls. The microaneurysms, which
resemble tiny blisters on the blood vessels, may leak blood onto the central retina, or macula, causing an early,
sight-impairing swelling of this area called macular edema.
The disease enters its proliferative stage when new blood vessels begin to grow into the retina and optic disc to
increase blood flow to these tissues. New blood vessels may form because of hormonal signals, i.e., growth
hormone, sent to the eye. These new blood vessels are fragile and often leak blood and protein into the vitreous--
the transparent gel that fills two-thirds of the inner eye--and retina, causing visual impairment.
As the disease progresses, the new blood vessels may also grow into the vitreous and cause it to detach
gradually from the back of the eye. As the vitreous pulls away, it may detach the retina as well. As a result, severe
visual loss or blindness will occur.
What are the symptoms of diabetic retinopathy?
For many people with diabetic retinopathy, there are no early symptoms. There is no pain, no blurred vision, and
no ocular inflammation. In fact, many people do not develop any visual impairment until the disease has
advanced well into its proliferative stage. At this point, the vision that has been lost cannot be restored.
However, some people in the early and advanced stages of diabetic retinopathy may notice a change in their
central and/or color vision. The loss of central vision results from macular edema, which can often be effectively
How is diabetic eye disease detected?
Because diabetic eye disease often has no early symptoms, it is detected during a comprehensive eye
examination through dilated pupils. Dilation consists of the eye care professional's placing medicated drops into
the eye to enlarge the pupil. By doing so, the practitioner can better examine the back of the eye for early signs
of disease, such as microaneurysms, before noticeable vision loss occurs.
For example, if the eye care professional detects diabetic retinopathy early, he or she can then monitor the
patient's condition and determine the best time to treat the problem, should it progress to that point. The National
Eye Health Education Program--coordinated by the National Eye Institute, one of the Federal National Institutes of
Health--recommends that people with diabetes undergo a comprehensive eye examination through dilated pupils
at least once a year.
How is diabetic retinopathy treated?
Laser surgery, also called photocoagulation, is now being used successfully to treat proliferative retinopathy. It is
performed by aiming a narrow, high-energy beam of light through the pupil and onto the retina. The beam of light
is used to make hundreds of small burns over the retinal surface that destroy the growing blood vessels.
Laser surgery is also used to treat macular edema. In this procedure, however, the laser is aimed directly onto
leaking blood vessels in the macula. The beam of light then seals the blood vessels to stop their sight-impairing
Current treatment guidelines are so successful that even people with proliferative retinopathy have a 90 percent
chance of maintaining their vision. Current treatment guidelines call for (1) regular eye examinations through
dilated pupils, (2) timely laser surgery, and (3) when needed, vitrectomy, a surgical procedure that clears
hemorrhaged blood that can cloud vision from inside the eye.
The Diabetes Control and Complications Trial (DCCT) showed that better control of blood sugar levels slows the
onset and progression of retinopathy and lessens the need for laser surgery for severe retinopathy.
What research is being conducted?
During the past 25 years, scientists have made great progress in managing and treating diabetic eye disease.
Laser surgery, cataract surgery, and glaucoma medications and surgery have all been either developed or
improved considerably during this period. But if this research progress is to continue, additional understanding is
needed of the cellular and biochemical basis of each disease.
For example, NEI scientists have developed the first animal research model for advanced (proliferative)
retinopathy. This model will allow researchers to study better the vascular changes associated with this disease. It
will also allow them to initiate studies on new drugs that are designed to prevent and treat diabetic retinopathy.
Other NEI-funded scientists are studying several growth factors to determine whether they influence the
development of weak new blood vessels that proliferate in advanced diabetic retinopathy. In other studies, NEI
scientists have inoculated bacterial cells with the DNA sequence that codes for the enzyme aldose reductase,
which has been demonstrated as being a major mechanism by which early retinal capillary cells break down in the
formation of diabetic retinopathy. The inoculated cells are yielding abundant and active aldose reductase, which
is valuable for use in the development of a safe and effective enzyme inhibitor.
A well-coordinated public health effort also requires accurate data on disease prevalence, progression, and
associated factors. For this reason, the NEI is supporting a long-term epidemiologic study in southern Wisconsin
on diabetic retinopathy.
As science moves forward in its study of diabetic eye disease, it is likely that new treatments will be a result of
basic and clinical research. Improved treatment, coupled with heightened public awareness, should go far toward
reducing diabetic eye disease as a future national health problem.
© Copyright 1999 Dialog Medical, Inc. All rights reserved.
|Midwest Retina Associates, Inc.